Shilpa Medicare Ltd - SHILPA MEDICARE Share Price

Sector: Pharmaceuticals | ISIN: INE790G01031
₹ 238.95 (4.05%) icon7 Jun, 2023, 3:59:20 PM
Open
₹ 231.30
Prev. Close
₹ 229.65
Turnover(lac)
₹ 9,010.79
Day's High
₹ 249.60
Day's Low
₹ 231.30
52 Wk High
₹ 457.00
52 Wk Low
₹ 222.60
Book Value
₹ 244.56
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 2,074.13
P/E
0.00
EPS
0.00
Div. Yield
0.00

Shilpa Medicare Ltd Stock View

info icon
Edit Image
HOLD
Target | 17 Nov, 2022 292 (20.76%)

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. It is... Read More

Shilpa Medicare Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 6/7/2023 3:59:20 PM

    ₹ 238.95 9.30 4.05
  • Open
  • ₹ 231.3
  • Prev. Close
  • ₹ 229.65
  • Turnover(Lac.)
  • ₹ 9,011
  • Day's High
  • ₹ 249.6
  • Day's Low
  • ₹ 231.3
  • 52 Week's High
  • ₹ 457
  • 52 Week's Low
  • ₹ 222.6
  • Book Value
  • ₹ 244.56
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 2,074.13
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Shilpa Medicare Ltd Corporate Actions

17 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Feb , 2023

12:00 AM

03 Feb , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Nov , 2022

12:00 AM

19 Aug , 2022

12:00 AM

AGM

Announcement date: 19 Aug , 2022

View Details

23 May , 2022

12:00 AM

Dividend

Dividend amount: 1.1
Announcement date: 23 May , 2022

View Details

03 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Aug , 2022

12:00 AM

16 Aug , 2022

12:00 AM

BookCloser

View Details

Shilpa Medicare Ltd SHAREHOLDING SNAPSHOT
07 June , 2023 | 10:26 PM

PROMOTER - TOTAL50.01%

Indian: 50.01%

Foreign: 0%

NON-PROMOTER - TOTAL 49.99%

Institutions: 14.28%

Non-Institutions: 35.71%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Shilpa Medicare Ltd News and Update

Image not found
  • 7 hours ago |
  • 5:52 PM

The venture aims to cater to discerning consumers seeking design-led, bespoke, and high-quality jewelry.

Article Image
Image not found
Image not found
ad IconAd Image

Shilpa Medicare Ltd FINANCIALS

Shilpa Medicare Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Shilpa Medicare Ltd

  • Omprakash Inani
  • Chairman (Non-Executive)
  • Vishnukant Bhutada
  • Managing Director
  • Pramod Kasat
  • Non-Exec. & Independent Dir.
  • Rajender Sunki Reddy
  • Non-Exec. & Independent Dir.
  • Sirisha Chintapalli
  • Non-Exec. & Independent Dir.
  • Sharath Reddy Kalakota
  • Whole-time Director
  • Arvind Vasudeva
  • Independent Director
  • Hetal Gandhi
  • Independent Director
  • Ritu Tiwary
  • Company Sec. & Compli. Officer
  • Kamal K Sharma
  • Addtnl Independent Director
  • Anita Bandyopadhyay
  • Addtnl Independent Director

Summary

Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SMLs underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SMLs product range includes over 44 oncology and non-oncology APIs. The Companys formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SMLs wholly owned subsidiary Shilpa... Read More


Reports by Shilpa Medicare Ltd


Reports by Shilpa Medicare Ltd